Clinical Trials for Partial Lipodystrophy
There are currently 2 ongoing clinical trials investigating treatment options for partial lipodystrophy, a rare disorder where the body cannot store fat properly in certain areas. Both trials are evaluating metreleptin, a hormone replacement therapy administered as a daily injection under the skin, to help manage metabolic complications associated with this condition.
Clinical trial locations
- Belgium
- France
- Germany
- Italy
- Netherlands
- Poland
- Spain
Study on the Effects of Metreleptin for Patients with Partial Lipodystrophy
This trial is evaluating the effectiveness and safety of metreleptin in patients with partial lipodystrophy over a 24-month treatment period. The study is being conducted in Italy, France, and Germany.
Main inclusion criteria: Patients must be at least 12 years old with a confirmed diagnosis of partial lipodystrophy. They need to have either elevated blood sugar levels (HbA1c of 6.5% or higher) or high fasting triglycerides (500 mg/dL or higher). Standard treatments must have failed to control their condition, and patients should have been on stable doses of diabetes medication for at least 90 days or fat-lowering medication for at least 6 weeks. Female patients of childbearing age must use effective birth control methods during the study and for 4 weeks after the last dose. Patients must be willing to follow dietary recommendations and continue their current medications without significant dose changes.
Main exclusion criteria: Patients with conditions other than partial lipodystrophy cannot participate. Those who are pregnant or breastfeeding, have serious health conditions that might interfere with the study, are not within the specified age range, or are currently participating in another clinical trial are excluded from this study.
Study focus: The trial aims to evaluate how metreleptin affects key health markers in patients with partial lipodystrophy. Researchers will monitor changes in glycated hemoglobin (HbA1c) and triglyceride levels at 12 and 24 months. The goal is to observe a decrease of at least 0.5% in HbA1c levels or improvements in triglyceride levels. The study will also assess the body’s immune response to the treatment and overall safety throughout the two-year period.
Investigational drug: Metreleptin is administered daily as a subcutaneous injection under the skin. It works by supplementing leptin, a hormone that helps regulate energy balance and fat storage in the body. The medication is available in formulations of 5.8 mg, 11.3 mg, and 3 mg powder for solution for injection, with specific dosages determined based on individual patient needs.
Study on Metreleptin for Patients with Partial Lipodystrophy
This trial is investigating the safety and effectiveness of metreleptin compared to placebo in patients with familial partial lipodystrophy over a 12-month treatment period. The study is being conducted in Belgium, the Netherlands, Spain, and Poland.
Main inclusion criteria: Patients must be at least 12 years old with a diagnosis of familial partial lipodystrophy, which can be confirmed through physical examination, genetic testing, or family history. They need to have poor metabolic control, defined as HbA1c of 7% or higher or fasting triglycerides of 500 mg/dL or higher. Patients with diabetes and elevated HbA1c should be on stable diabetes treatment for at least 3 months before the study. Those with high triglycerides should be on stable lipid-lowering treatment for at least 6 weeks. Female patients of childbearing potential must use highly effective birth control methods, including a barrier method in addition to hormonal contraception. Patients must be willing to follow dietary restrictions and provide informed consent, with parental consent required for those under 18.
Main exclusion criteria: Patients with serious medical conditions that might interfere with the study, those who are pregnant or breastfeeding, individuals with recent major surgery, uncontrolled high blood pressure, severe liver or kidney disease, or a history of heart disease are excluded. Patients with a history of drug or alcohol abuse, allergies to the study medication, or those unable to comply with study procedures cannot participate. Those currently participating in another clinical trial are also excluded.
Study focus: This is a double-blind, placebo-controlled trial where participants are randomly assigned to receive either metreleptin or placebo. The study monitors changes in health markers such as blood sugar and triglyceride levels over the 12-month treatment period, with a comprehensive mid-study evaluation at 6 months and a final evaluation at the end of treatment. A 4-week follow-up period after the last dose allows researchers to monitor for any delayed effects. The trial aims to determine whether metreleptin can safely and effectively help people with familial partial lipodystrophy manage their condition and improve metabolic health.
Investigational drug: Metreleptin is given as a daily self-administered subcutaneous injection under the skin. The medication replaces leptin, a hormone that is usually low in people with lipodystrophy, helping to regulate the body’s energy balance and improve metabolic health. In this trial, participants receive either Myalepta 11.3 mg or a matching placebo.
Summary
Both ongoing clinical trials for partial lipodystrophy are focused on evaluating metreleptin, a hormone replacement therapy administered as daily subcutaneous injections. The trials are distributed across seven European countries, with one study conducted in Italy, France, and Germany over 24 months, and the other in Belgium, the Netherlands, Spain, and Poland over 12 months. Both studies target similar patient populations with metabolic complications, including elevated blood sugar and triglyceride levels, though they differ in their specific diagnostic criteria and treatment duration. The consistent focus on metreleptin across both trials highlights its potential as a treatment option for managing the metabolic complications associated with this rare condition.
